Unique and multifaceted mechanism of action
- Tumour antigen-specific IgE binds very tightly to FcεRI receptor on surface of myeloid cells such as macrophages
- Facilitates tissue immunosurveillance by IgE-activated macrophages
- IgE-activated macrophages permeate tumour and release pro-inflammatory mediators
- Attracts and activates CD4+ and CD8+ T cells which destroy the tumour
Allows combinations with other modalities
- IgE has demonstrated strong single agent activity in vivo in a variety of settings
- Unique MoA allows combination with other modalities such as CPIs and ADCs
- IgE successfully combines in vivo with CPIs in HER2-low breast cancer model
Potent activity in ultra-low antigen cancers
- IgE has potent activity against tumour cells expressing ultra-low levels of FR⍺ and HER2
- In vivo Proof of Concept in triple-negative breast cancer achieved
- MOv18 IgE has demonstrated clinical activity in patients with low FR⍺
IgE Lights the Macrophage Fuse which Detonates the T Cell Bomb
- IgE causes tumour antigen-specific macrophage permeation
of tumour - Pro-inflammatory cytokines and chemokines released
- Cytokines attract and activate T cells inside tumour
- T cells destroy tumour